PD-L1 expression in neuroendocrine tumors of the lung

Kenjiro Tsuruoka, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Keisuke Asakura, Kazuo Nakagawa, Hiroyuki Sakurai, Shun ichi Watanabe, Koji Tsuta, Yuichiro Ohe

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. Methods The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0–3] × stained area [0–100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Results Among the 227 patients included in this study, the patient demographics were as followsmedian age (range), 65 years (19–84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV)79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC)46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as followsTC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). Conclusions PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalLung Cancer
Volume108
DOIs
Publication statusPublished - 2017 Jun 1

Keywords

  • Carcinoid
  • Clone E1L3N
  • Immunohistochemistry
  • LCNEC
  • Neuroendocrine
  • PD-1
  • PD-L1
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'PD-L1 expression in neuroendocrine tumors of the lung'. Together they form a unique fingerprint.

  • Cite this

    Tsuruoka, K., Horinouchi, H., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., Yamamoto, N., Asakura, K., Nakagawa, K., Sakurai, H., Watanabe, S. I., Tsuta, K., & Ohe, Y. (2017). PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 108, 115-120. https://doi.org/10.1016/j.lungcan.2017.03.006